Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Clinical trial NCT05256290 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05256290
Sponsor: Black Diamond Therapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Advanced Non-Small Cell Squamous Lung Cancer Metastatic Lung Non-Small Cell Carcinoma Metastatic Lung Cancer NSCLC Advanced Lung Carcinoma Epidermal Growth Factor Receptor C797S Epidermal Growth Factor Receptor G719X EGF-R Positive Non-Small Cell Lung Cancer EGFR-TKI Resistant Mutation

Start date: 2022-03-31
Primary completion: 2025-11-03
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.